A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Overview

The purpose of this study is to determine the treatment efficacy of CYH33 monotherapy in patients with recurrent or persistent ovarian, fallopian tube or primary peritoneal clear cell carcinoma, who received prior systemic anti-tumor treatment.

Full Title of Study: “A Phase II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of CYH33, a Selective PI3Kα Inhibitor in Patients With Recurrent/Persistent Ovary, Fallopian Tube or Primary Peritoneal Clear Cell Carcinoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 30, 2023

Detailed Description

The purpose of this study is to determine whether treatment with single agent CYH33 significantly improves ORR compared to historical efficacy data in patients with recurrent/persistent ovarian clear cell carcinoma (OCCC) harboring PIK3CA hotspot mutations who received prior systemic anti-tumor treatment.

Interventions

  • Drug: CYH33
    • a Selective PI3Kα Inhibitor

Arms, Groups and Cohorts

  • Experimental: CYH33
    • 40mg daily

Clinical Trial Outcome Measures

Primary Measures

  • Tumor ORR in patients with PIK3CA hotspot mutations.
    • Time Frame: through study completion, an average of 1 year
    • Tumor ORR per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 in patients with PIK3CA hotspot mutations.

Secondary Measures

  • ORR in patients without PIK3CA hotspot mutations.
    • Time Frame: through study completion, an average of 1 year
    • ORR per RECIST v1.1 in patients without PIK3CA hotspot mutations.
  • PFS
    • Time Frame: through study completion, an average of 1 year
    • PFS by BIRC using RECIST v1.1
  • OS
    • Time Frame: through study completion, an average of 2 year
    • OS in each of the PIK3CA mutation status cohort
  • genetic and protein biomarker alterations
    • Time Frame: through study completion, an average of 1 year
    • genetic and protein biomarker alterations that can impact PI3K signaling pathway

Participating in This Clinical Trial

Main Inclusion Criteria:

1. Female patients ≥ 18 years of age 2. Provide informed consent voluntarily. 3. Patients must have histologically or cytologically confirmed recurrent or persistent ovarian, fallopian tube, or peritoneum clear cell carcinoma. 4. Patients with recurrent/persistent ovary, fallopian tube or primary peritoneal clear cell carcinoma, who have identified PIK3CA status (with or without PIK3CA hotspot mutations). 5. Patients must have failed standard chemotherapy. 6. ECOG-PS ≤ 1. 7. Patient must have adequate organ and bone marrow function measured within 28 days of screening. Main Exclusion Criteria:

Patients are ineligible for this study if they meet any of the following criteria: 1. Patient has received any anticancer therapy 2. Patients who had prior treatment with any PI3K, mTOR or AKT inhibitor. 3. Radical radiation therapy within 4 weeks prior to the first dose of the investigational product or received local palliative radiation therapy for bone metastases within 2 weeks. 4. Any toxicities from prior treatment that have not recovered to baseline. 5. Patients who have been treated with any hematopoietic colony-stimulating growth factors ≤ 2 weeks prior to starting study drug. 6. Patients who have symptomatic CNS metastasis. 7. Major surgery or had significant traumatic injury within 28 days prior to the first dose of the investigational product or has not recovered from major side effects. 8. Known HIV infection with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunity infection within the past 12 months; active hepatitis B and hepatitis C. 9. History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis. 10. Patients with clinically significant cardiovascular disease

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Haihe Biopharma Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.